Premium
Plasminogen activator inhibitor 1 in human carcinoma tissues
Author(s) -
Tanaka Nobuya,
Fukao Hideharu,
Ueshima Shigeru,
Okada Kiyotaka,
Yasutomi Masayuki,
Matsuo Osamu
Publication year - 1991
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910480402
Subject(s) - carcinoma , stomach , pathology , plasminogen activator , biology , medicine , endocrinology , biochemistry
The content of PAI‐1 was measured in carcinoma tissues from the stomach and colorectum divided macroscopically into 3 portions: the central part of the carcinoma, the marginal part of the carcinoma containing some normal mucosa, and the normal mucosa. Among these tissues, the highest levels of PAI‐1 antigen were found in the central part of the carcinoma. On the other hand, no PAI‐1 antigen or activity was observed in the normal mucosae. The PAI‐1 produced in the stomach and colorectal carcinoma tissues showed a non‐lytic zone with a molecular weight of 54 kDa by reverse fibrin autography, and this 54‐kDa band reacted with anti‐PAI‐1 IgG on an immunoblotted nitrocellulose membrane by the avidinbiotin complex method. The contents of PAI‐2 in the carcinoma tissues were not significantly different from those in the normal mucosa of the stomach and colorectum. In both the stomach and colorectal carcinomas, the highest value of u‐PA/total PA (sum of u‐PA and t‐PA) was observed in the central part of the carcinoma, followed by the marginal part of the carcinoma, and was lowest in the normal mucosa. We conclude that increased levels of PAI‐1 in malignant tissue of the stomach and colorectal tract may serve to modulate extra‐cellular proteolysis by u‐PA.